SSPE detected only on multidetector CTPA may not be clinically significant. In contrast, den Exter and colleagues 7 found that in 116 patients with SSPE and 632 patients with proximal PE, recurrent VTE rates did not differ between the groups (3.6% vs 2.4%, respectively). This study, however, reported higher than expected mortality rates (10.3% in SSPE and 6.3% in proximal PE). On close examination, the patients included in the study had a high prevalence of comorbidities, particularly malignant neoplasm. In addition, many of the patients had concomitant DVT and would not have been candidates for clinical observation alone.
There are no randomized clinical trials addressing this topic. Although a large prospective cohort study is currently ongoing in Canada and Europe (NCT01455818), it is still in the enrollment phase with results not expected for an additional 18 months (M. Carrier, MD, lead investigator, written communication, May 2018). Given the current body of evidence, authors of the most recent American College of Chest Physicians Antithrombotic Guidelines 9 suggested an individualized approach to patient management. The authors recommend first assessing the likelihood that the CTPA is a true positive result. Factors that favor a true positive result include a high-quality CTPA, multiple intraluminal filling defects, defects involving more proximal subsegmental vessels, defects seen on more than 1 image or projection, defects that are surrounded by contrast rather than appearing adherent to the vessel wall, symptomatic patient, high clinical pretest probability for acute PE, or an unexplained elevated D-dimer level. Plasma concentrations of D-dimer have been shown to correlate with clot burden. 2 In instances in which there is a high level of suspicion of a false-positive result, the high risk of bleeding should lead to the avoidance of anticoagulation. In patients believed to have a true, clinically relevant SSPE (without DVT, which would warrant treatment), the decision to anticoagulate should be based on an assessment of the patient's risk of recurrence, cardiopulmonary reserve, and risk of bleeding. In low-risk patients with adequate reserve, or in patients with high bleeding risk, clinical surveillance is favored. Factors that might lead to the decision to anticoagulate include the presence of active malignant neoplasm, idiopathic clot, marked symptoms, or patient preference. Although the majority of the cohort of patients that Raslan and colleagues 5 are reporting on predated the publication of the recent guidelines, their data nonetheless highlight the issue of overtreatment of SSPE and the potential harm associated with it. Pending future management trials, the clinical equipoise that practitioners face with SSPE should, at a minimum, mandate a conversation with the patient regarding the advantages and disadvantages of anticoagulation treatment in SSPE. 
Lisa K. Moores, MD, MACP

Assessment of Patterns of Potentially Unsafe Use of Zolpidem
Zolpidem was the most widely used prescription hypnotic medication and the fourth most frequently prescribed psychiatric drug in 2013. 1 It achieves its effects as an agonist of γ-aminobutyric acid (GABA) receptors. However, the prescribing information 2 and US Food and Drug Administration (FDA) Drug Safety Communications 3 include limitations to reduce adverse effects, including (1) short-term use because of loss of efficacy; (2) a lower dose of 5 mg/d for those 65 years or older, and the lower starting dose for women because of 45% to 50% higher blood concentrations 2 ; and (3) increased risks when combined with other central nervous system (CNS)-depressant drugs. These precautions were intended to reduce the risks of next-day impairment, abnormal behavioral changes, and dependency. We compared patterns of reported use with these recommendations in data from the largest publicly available national survey of prescription medication. The lower recommended daily dose was 5 mg for immediate and 6.25 mg for extended release products; the higher daily dose was 10 mg or 12.5 mg. Sustained use was defined as 3 or more prescriptions or 61 days or more of supply. Other drugs sharing CNS-depressant effects were any opioid agonist, any other GABA agonist (primarily benzodiazepines), and any form of synthetic GABA (primarily gabapentin). Multiple CNS-depressant risks were limited to those reporting sustained use of the CNS medications. We estimated the exposed populations and 95% confidence intervals (CIs) using the MEPS multistage probability design, based on a clustered sample of 35 427 individuals and 330 453 reported prescriptions during 2015. Because this was not a study with direct patient participants, no informed consent was needed, and since any personal information was deidentified in this publicly available research survey, institutional review board approval was not sought.
Results | Overall, 3.8 million adults (95% CI, 3.2-4.4 million) aged 18 to 85 years reported 1 or more prescriptions for zolpidem in 2015. Population characteristics, detailed in Discussion | These data show that optimal safe use of zolpidem is uncommon. Although efficacy declines substantially after 14 days of continuous administration, 5 most zolpidem patients reported sustained use, with increased risk of dependence, given that zolpidem is a class IV controlled substance. Overdose and next-day impairment risks were increased with the 41.4% combining zolpidem with sustained use of other CNS-depressant drugs. These data have several limitations. They are not capable of assessing the harms of zolpidem, only selfreported patterns of drug use. Some women reporting the higher zolpidem dose could have been started at the recommended 5-mg daily dose and later increased the dose. MEPS data likely underestimate exposure because they are selfreported, and the data could not account for the start of medication use and permanent discontinuation occurring part way through the 12-month survey period. Other key safe use recommendations-abstaining from alcohol, avoiding over-the-counter sleep aids, and limiting next-day driving-could not be assessed in these data. In conclusion, this study of zolpidem shows that there are many opportunities to reduce the risks of next-day impairment, abnormal behavior changes, and dependence. 
Letters
Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine
In 2017, the Advisory Committee on Immunization Practices (ACIP) voted to recommend a new recombinant adjuvanted zoster subunit vaccine (RZV) over the live attenuated zoster vaccine (ZVL) and to lower the vaccination age to 50 years. They also recommended that previously vaccinated individuals receive an immediate booster with RZV. 1 We evaluated the cost-effectiveness of these recommendations.
Methods | We used our previous Markov model 2 to compare costs and quality-adjusted life-years (QALYs) for RZV vs no vaccination with variation of vaccination age from 50 to 59 years. We then adapted the model structure 3 to include an RZV booster 0 to 10 years after ZVL administered at 60, 70, and 80 years of age. Patients began the first model in the unvaccinated state and the second in the ZVL vaccinated state and underwent lifelong follow-up. In each yearly cycle, patients undergo transitional events, including herpes zoster infection and related complications, before entering the next cycle. This study used data extracted from the literature; therefore, institutional review board was not needed. We calculated the incremental cost-effectiveness ratio (ICER) with willingness-to-pay thresholds of $50 000/QALY and $100 000/QALY. We conducted base-case, 1-way, and probabilistic sensitivity analyses from the societal perspective, using TreeAge Pro 2017 software (version R2.1; TreeAge Software, Inc). Costs, adjusted for inflation, were expressed in 2016 US dollars. Costs and QALYs were discounted at 3% per year. Model inputs have been described in detail previously.
2,4
Results | At 50 years of age, RZV had an ICER of $151 430/QALY, which declined below $100 000/QALY at 53.2 years and below $50 000/QALY at 57.1 years (Figure 1) . Higher adherence to the second dose made RZV cost-effective at younger ages.
Varying the following inputs produced an ICER below $100 000/QALY: probability of postherpetic neuralgia lasting at least 12 months, QALY loss due to herpes zoster infection, efficacy waning rate, and cost of RZV. In the probabilistic sensitivity analysis, RZV at 50 years of age had only a 23% chance of being cost-effective.
The immediate RZV booster had an ICER of greater than 100 000/QALY at all ages (Figure 2) . In people vaccinated with ZVL at 60 years of age, a booster was cost-effective at thresholds of $50 000/QALY and $100 000/QALY after 6 and 4 years, respectively. If adherence was 100%, immediate revaccination would be reasonable. Only changes in the efficacy-waning rate of RZV produced ICERs of less than $100 000/QALY. In the probabilistic sensitivity analysis, the immediate booster had a 9% chance of being cost-effective; the 5-year booster had a 75% chance. Adherence rate = 56% ZVL vaccination at age 60 y ZVL vaccination at age 70 y ZVL vaccination at age 80 y Adherence rate = 100% ZVL vaccination at age 60 y ZVL vaccination at age 70 y ZVL vaccination at age 80 y Adherence rates for 2 doses of RZV were assumed to be 56% and 100%. QALY indicates quality-adjusted life-year; RZV, recombinant adjuvanted zoster vaccine; and ZVL, live attenuated zoster vaccine. 
